Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from AnaptysBio ( (ANAB) ) is now available.
AnaptysBio, Inc. is a biotechnology company that is spinning out First Tracks Biotherapeutics as a separate, clinical-stage biotech focused on next-generation antibody therapeutics targeting immune pathways in autoimmune and inflammatory diseases. First Tracks Bio’s initial pipeline includes ANB033 for celiac disease and eosinophilic esophagitis, rosnilimab for rheumatoid arthritis, and ANB101, supported by an initial cash balance of $180 million and an expected two-year cash runway.
On March 26–27, 2026, AnaptysBio detailed the planned April 20, 2026 spin-off of First Tracks Bio, including a $80 million private placement that forms part of First Tracks’ $180 million launch capital, a one-for-one share distribution to Anaptys stockholders, and Nasdaq listing under the ticker TRAX. The company also terminated its ATM equity program, appointed Susannah Gray to its board, and set executive transition and separation agreements with Dennis Mulroy and Eric Loumeau as Anaptys refocuses on royalty management while First Tracks drives drug development.
The most recent analyst rating on (ANAB) stock is a Hold with a $66.00 price target. To see the full list of analyst forecasts on AnaptysBio stock, see the ANAB Stock Forecast page.
Spark’s Take on ANAB Stock
According to Spark, TipRanks’ AI Analyst, ANAB is a Neutral.
The score is driven by improved 2025 financial trajectory (revenue acceleration and positive operating/free cash flow) and strong technical uptrend. Offsetting this are still-negative earnings with consistently negative gross profit and an unattractive/limited valuation signal due to the negative P/E and no dividend data.
To see Spark’s full report on ANAB stock, click here.
More about AnaptysBio
AnaptysBio, Inc. is a biotechnology company that is spinning out First Tracks Biotherapeutics as a separate, clinical-stage biotech focused on next-generation antibody therapeutics targeting immune pathways in autoimmune and inflammatory diseases. First Tracks Bio’s initial pipeline includes ANB033 for celiac disease and eosinophilic esophagitis, rosnilimab for rheumatoid arthritis, and ANB101, supported by an initial cash balance of $180 million and an expected two-year cash runway.
On March 26–27, 2026, AnaptysBio detailed the planned April 20, 2026 spin-off of First Tracks Bio, including a $80 million private placement that forms part of First Tracks’ $180 million launch capital, a one-for-one share distribution to Anaptys stockholders, and Nasdaq listing under the ticker TRAX. The company also terminated its ATM equity program, appointed Susannah Gray to its board, and set executive transition and separation agreements with Dennis Mulroy and Eric Loumeau as Anaptys refocuses on royalty management while First Tracks drives drug development.
Average Trading Volume: 514,017
Technical Sentiment Signal: Buy
Current Market Cap: $1.87B
For a thorough assessment of ANAB stock, go to TipRanks’ Stock Analysis page.